Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.
Rimsza LM, Wright G, Schwartz M, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Cook JR, Tubbs RR, Braziel RM, Delabie J, Miller TP, Staudt LM. Rimsza LM, et al. Among authors: miller tp. Clin Cancer Res. 2011 Jun 1;17(11):3727-32. doi: 10.1158/1078-0432.CCR-10-2573. Epub 2011 Mar 1. Clin Cancer Res. 2011. PMID: 21364035 Free PMC article.
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.
Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM. Rimsza LM, et al. Among authors: miller tp. Blood. 2004 Jun 1;103(11):4251-8. doi: 10.1182/blood-2003-07-2365. Epub 2004 Feb 19. Blood. 2004. PMID: 14976040 Free article.
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.
Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, Zettl A, Rosenwald A, Ott G, Muller-Hermelink HK, Delabie J, Fisher RI, Unger JM, Leblanc M, Staudt LM, Jaffe ES, Gascoyne RD, Chan WC, Weisenburger DD, Greiner T, Braziel RM, Miller TP. Rimsza LM, et al. Among authors: miller tp. Blood. 2006 Feb 1;107(3):1101-7. doi: 10.1182/blood-2005-04-1510. Epub 2005 Oct 20. Blood. 2006. PMID: 16239429 Free PMC article.
Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival.
Roberts RA, Wright G, Rosenwald AR, Jaramillo MA, Grogan TM, Miller TP, Frutiger Y, Chan WC, Gascoyne RD, Ott G, Muller-Hermelink HK, Staudt LM, Rimsza LM. Roberts RA, et al. Among authors: miller tp. Blood. 2006 Jul 1;108(1):311-8. doi: 10.1182/blood-2005-11-4742. Epub 2006 Mar 16. Blood. 2006. PMID: 16543468 Free PMC article.
Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma.
Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Unger JM, Botros IW, Rounseville MP, Seligmann BE, Miller TP, Grogan TM, Rimsza LM. Roberts RA, et al. Among authors: miller tp. Lab Invest. 2007 Oct;87(10):979-97. doi: 10.1038/labinvest.3700665. Epub 2007 Aug 13. Lab Invest. 2007. PMID: 17700562 Free article.
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.
Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Rimsza LM, et al. Among authors: miller tp. Blood. 2008 Oct 15;112(8):3425-33. doi: 10.1182/blood-2008-02-137372. Epub 2008 Jun 10. Blood. 2008. PMID: 18544678 Free PMC article.
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM. Dave SS, et al. Among authors: miller tp. N Engl J Med. 2004 Nov 18;351(21):2159-69. doi: 10.1056/NEJMoa041869. N Engl J Med. 2004. PMID: 15548776 Free article.
Molecular diagnosis of Burkitt's lymphoma.
Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. Dave SS, et al. Among authors: miller tp. N Engl J Med. 2006 Jun 8;354(23):2431-42. doi: 10.1056/NEJMoa055759. N Engl J Med. 2006. PMID: 16760443 Free article.
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Press OW, et al. Among authors: miller tp. Clin Cancer Res. 2013 Dec 1;19(23):6624-32. doi: 10.1158/1078-0432.CCR-13-1120. Epub 2013 Oct 15. Clin Cancer Res. 2013. PMID: 24130072 Free PMC article.
251 results